Brought to you by 
Series C lands €14.5mm for Enterome
02 May 2016
Executive Summary
Enterome Bioscience SA (microbiome-based therapeutics and diagnostics) raised €14.5mm ($16.4mm) in its Series C financing led by returning shareholders Seventure and Lundbeckfond Ventures, which were joined by first-time backer Nestle Health Science. The company will use the proceeds to move its lead IBD candidate, EB8018, into the clinic this year. Enterome licensed EB8018 from Vertex just two days prior to the Series C round.
Deal Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Series C lands €14.5mm for Enterome
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice